Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-01

Study Completion Date

2021-11-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.

NCT06654726

Primary Sclerosing Cholangitis

WITHDRAWN PHASE2/PHASE3

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

NCT05130047

Chronic Diarrhea Irritable Bowel Syndrome With Diarrhea Bile Acid Malabsorption +3 more

COMPLETED PHASE2

Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis

NCT02024295

Hepatitis, Alcoholic

UNKNOWN PHASE4

Dietary Allowance of Methyl Donor Nutrients to Minimize Risks of Non-alcoholic Fatty Liver Progression

NCT05291104

Non-alcoholic Fatty Liver Disease

UNKNOWN NA

AST-120 Used to Treat Mild Hepatic Encephalopathy

NCT00867698

Mild Hepatic Encephalopathy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Impaired Hepatic Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Child-Pugh A (Mild Hepatic Impairment) & Healthy Matched

Administered by subcutaneous injection

Group Type EXPERIMENTAL

Aldafermin

Intervention Type BIOLOGICAL

Biological: Aldafermin (NGM282) Subcutaneous Injection

Child-Pugh B (Moderate Hepatic Impairment) & Healthy Matched

Administered by subcutaneous injection

Group Type EXPERIMENTAL

Aldafermin

Intervention Type BIOLOGICAL

Biological: Aldafermin (NGM282) Subcutaneous Injection

Child-Pugh C (Severe Hepatic Impairment) & Healthy Matched

Administered by subcutaneous injection

Group Type EXPERIMENTAL

Aldafermin

Intervention Type BIOLOGICAL

Biological: Aldafermin (NGM282) Subcutaneous Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aldafermin

Biological: Aldafermin (NGM282) Subcutaneous Injection

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NGM282

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females, 18 - 75 years of age, inclusive
2. Able to comprehend and willing to sign an informed consent form (ICF)
3. Willing and able to comply with all study requirements
4. BMI 18 - 40 kg/m2, inclusive at Screening
5. Stable medication regimen - no medication initiation or dose change within 7 days or 5 half-lives (whichever is longer) prior to dosing of the study medication.
6. Non-pregnant, non-lactating females. Female subjects of childbearing potential and male subjects with a female sexual partner of childbearing potential must agree to consistent and adequate birth control. One of the following forms of contraception is required:

1. Condom
2. Hormone containing contraceptive
3. Intrauterine device with a failure rate \< 1% per year
4. Cervical cap or diaphragm with spermicidal agent
5. Tubal sterilization
6. Vasectomy in male partner
7. Sexual abstinence
7. Negative test for drugs of abuse at Screening unless they are currently prescribed
8. Negative human immunodeficiency virus (HIV) antibody screen at Screening

Exclusion Criteria

1. Any acute disease or condition being treated by medical therapy (prescription or over the counter) known to possibly impact hepatic function
2. History of or recent (\< 6 weeks) treatment for a chronic condition with a medication that is known to have hepatotoxic potential.
3. Any significant physical injury or surgical procedure within 6 weeks of Screening
4. Uncontrolled diabetes (hemoglobin A1c \[HbA1c\] \> 9.5%)
5. Uncontrolled hypertension (systolic blood pressure \[SBP\] \> 180 mmHg on ≥ 3 medications of different classes for blood pressure control)
6. Have received any investigational medication within 30 days or 5 half-lives, whichever is longer, prior to study dosing
7. Subjects should not have donated blood within 60 days of study entry or plasma within 7 days of study entry. Subjects must also refrain from blood donation from clinic admission, throughout the study period, and continuing for at least 30 days following the last dose of study medication.
8. Positive urine drug screen at Screening that is not otherwise explained by a permitted concomitant medication
9. History of alcoholism in the 6 months prior to Screening
10. Inadequate peripheral venous access

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes